Intravesical BCG therapy is effective in treating NMIBC, but it comes with side effects such as overactive bladder.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
The benefits of robotic surgery may have a more pronounced effect in octogenarians, according to investigators.
Findings refute the notion that variant histology MIBC will not respond to neoadjuvant chemotherapy.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Neoadjuvant chemotherapy prior to radical nephroureterectomy for upper tract urothelial carcinoma may improve pathologic outcomes regardless of age, new data suggest.
Investigators report increased risks for adverse pathology and 90-day readmission.
Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.
A mitomycin-containing reverse thermal gel could provide an alternative to repetitive surgeries for low-grade intermediate-risk NMIBC, according to investigators.
The risk for alzheimer disease decreased with increased dosing of BCG.
In addition to similar rates of overall survival, patients undergoing partial and radical cystectomy had comparable rates of upstaging to pT3-4 disease.
In this small study, even patients with high-risk tumors appeared to benefit from nephron-sparing surgery.
If validated, the EpiCheck® assay may identify more patients who can safely delay or avoid nephroureterectomy.
Older age independently predicted significant 48% lower odds of the gold standard treatment of NAC and radical cystectomy.
Study results support an attempt at bladder preservation in patients with BCG-unresponsive nonmuscle-invasive bladder cancer.
In a small study, most BCG-unresponsive patients who were initially managed conservatively ultimately underwent cystectomy.
Real-world data validate recently reported findings from clinical trials.
The approval was based on data from the phase 3 CheckMate-274 trial which evaluated nivolumab as an adjuvant treatment in 699 adults who have undergone radical surgery for invasive urothelial carcinoma at high risk of recurrence.
Vicineum is an investigational locally administered recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
Sacituzumab govitecan produced responses in all subgroups of patients.